Valtech Cardio Ltd., develops devices for the treatment of mitral valve regurgitation (MR), the most common heart valve disease. The company develops a range of products for transcatheter valve repair and replacement, based on the surgical gold standard, as well as repair products for open heart surgery that enable fine tuning on a beating heart.
Valtech addresses the three paths of the future of mitral treatment:
Treatment to high-risk surgical patients – expanding the availability of treatment to all patients
Less invasive repair/replacement – delivering surgical therapies through a catheter
More controlled surgical repair – size tuning on a beating heart for optimized results